ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Varenicline

Also written as “varenicline”, “Varenicline Tartrate” and “varenicline (CP-526,555)”.

Its studies are mostly in Smoking Cessation · Dry Eye Syndromes · Smoking · Trigeminal Neuralgia · Cigarette Smoking, led by 6 companies.

Drug pageVarenicline: every studyMany companies study it; this page follows only the 44 they lead. All 254 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 3, 200844 company-led studies, 1 open or runningNext primary completion: Feb 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer320 open or runningphase 4since Jan 3, 2008Aug 29, 2005none ahead
Viatrisits history only60 open or runningphase 3since Jul 25, 2019Aug 15, 2018none ahead
Corxel Pharmaceuticalsits history only20 open or runningphase 3since May 13, 2022May 13, 2022none ahead
Rose Research Centerits history only20 open or runningphase 4since Jun 6, 2019Jun 6, 2019none ahead
Kriya Therapeuticsits history only11 open or runningphase 2since Apr 17, 2026Apr 17, 2026Feb 2029phase 2 · NCT07596485
SRI Internationalits history only10 open or runningno phasesince Mar 8, 2006Mar 8, 2006none ahead

Also a collaborator on its studies: GlaxoSmithKline.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 17 studies since Aug 29, 2005.

  1. Mar 21, 2008Phase 3 study in Smoking CessationNCT00644969 · 128 enrolled · United States, Canada
  2. Apr 14, 2008Phase 1 study in Smoking CessationNCT00661765 · 18 enrolled · United States
  3. Jun 3, 2008Phase 4 study in Smoking CessationNCT00691483 · 659 enrolled · United States, Argentina, Brazil and more
  4. Jun 5, 2008Phase 1 study in HealthyNCT00694044 · 50 enrolled · United States
  5. Jul 15, 2008Phase 4 study in Tobacco Use CessationNCT00717093 · 432 enrolled · Norway, Sweden
  6. Aug 27, 20082 phase 2 studiesNCT00743847, NCT00744978
  7. Sep 9, 2008Phase 4 study in Smoking CessationNCT00749944 · 110 enrolled · United States
  8. Apr 28, 2009Phase 4 study in Smoking CessationNCT00889720 · 16 enrolled · France, Italy
  9. Feb 26, 2010Phase 4 study in Smoking CessationNCT01078298 · 525 enrolled · United States, Bosnia and Herzegovina, Croatia and more
  10. Nov 17, 2010Phase 4 study in Smoking CessationNCT01244061 · 498 enrolled · United States, Australia, Belgium and more
  11. Mar 9, 2011Phase 4 study in Smoking CessationNCT01312909 · 312 enrolled · United States, Canada, Georgia and more
  12. Jun 8, 2011Phase 4 study in Smoking CessationNCT01370356 · 1,510 enrolled · United States, Australia, Canada and more
  13. Oct 14, 2011Phase 4 study in Smoking CessationNCT01456936 · 8,144 enrolled · United States, Argentina, Australia and more
  14. Apr 6, 2012Phase 4 study in Smoking CessationNCT01574703 · 4,595 enrolled · United States, Argentina, Australia and more

TargetBeta

“Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
cytisineruleAchieve Life Sciencesphase 313

Studies

All 32 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01574703Smoking Cessation · United States, Argentina, Australia and more4CompletedJul 20154,595
NCT01456936Smoking Cessation · United States, Argentina, Australia and more4CompletedJan 20158,144
NCT01370356Smoking Cessation · United States, Australia, Canada and more4CompletedJul 20131,510
NCT01312909Smoking Cessation · United States, Canada, Georgia and more4CompletedJan 2018312
NCT01244061Smoking Cessation · United States, Australia, Belgium and more4CompletedNov 2012498
NCT01078298Smoking Cessation · United States, Bosnia and Herzegovina, Croatia and more4CompletedJun 2012525
NCT00889720Smoking Cessation · France, Italy4CompletedJul 201016
NCT00749944Smoking Cessation · United States4CompletedJul 2009110
NCT00744978Alzheimer Disease · Korea, Republic of2CompletedNov 201066
NCT00743847Schizophrenia2WithdrawnNov 20090
NCT00717093Tobacco Use Cessation · Norway, Sweden4CompletedApr 2009432
NCT00694044Healthy · United States1CompletedJun 200850
NCT00691483Smoking Cessation · United States, Argentina, Brazil and more4CompletedSep 2009659
NCT00661765Smoking Cessation · United States1CompletedJun 200818
NCT00644969Smoking Cessation · United States, Canada3CompletedApr 2010128
NCT00635401Smoking · Japan2Completed30
NCT00594204Smoking Cessation · Brazil, Colombia, Costa Rica and more4CompletedJun 2009593
NCT00527150Smoking Cessation · United States1CompletedFeb 200848
NCT00463918Smoking Cessation · United States, United Kingdom1Completed73
NCT00452894Smoking · China1Completed14
NCT00371813Smoking Cessation · China, Singapore, Thailand3Completed334
NCT00282984Smoking Cessation · United States, Argentina, Australia and more3CompletedNov 2007714
NCT00150254Smoking Cessation · United States2Completed625
NCT00150241Smoking Cessation · United States2Completed625
NCT00150228Smoking Cessation · United States2Completed300
NCT00143364Smoking Cessation · United States3Completed1,005
NCT00143325Smoking Cessation · United States, Belgium, France and more3Completed730
NCT00143299Smoking Cessation · United States, Australia3Completed375
NCT00143286Smoking Cessation · United States, Canada, Czech Republic and more3Completed2,000
NCT00141206Smoking Cessation · United States3Completed1,005
NCT00141167Smoking Cessation · Korea, Republic of, Taiwan3Completed250
NCT00139750Smoking Cessation · Japan2Completed600

How it is read

Names in the registry

  • “varenicline”, 11 entries
  • “Varenicline Tartrate”, 7 entries
  • “Varenicline”, 6 entries
  • “varenicline (CP-526,555)”, 6 entries
  • “CP-526,555 (varenicline)”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.